Lucence Presents Data at ESMO 2021 Showing Liquid Biopsy Detects Actionable Genomic Alterations in Bladder Cancer Patients Undergoing Immunotherapy

PALO ALTO, Calif.--(BUSINESS WIRE)-- #ESMO--Precision oncology company Lucence, in collaboration with researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, is sharing data highlighting the capabilities of its amplicon-based liquid biopsy technology to detect and characterize genomic alterations in ctDNA in patients with late-stage bladder cancer undergoing immunotherapy. The...

Click to view original post